Results 201 to 210 of about 941,378 (248)

Adrenergic Contraction of Human Prostate Tissues Is Maintained Under the Rab GTPase Inhibitors Nexhinib20 and CID1067700

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT α1‐Adrenoceptors are an important drug target in benign prostatic hyperplasia (BPH) and have been intensively studied at the expression level, but their posttranslational regulation in the prostate is widely unknown. Here we examined modulation of prostate smooth muscle contractions by inhibitors for RabGTPases, which are involved in ...
Luca Troffer   +9 more
wiley   +1 more source

Profiling Hydrolysis Rates of αS1‐Casein to αS1‐I‐Casein During Cheese Ripening by Intact‐Protein Liquid Chromatography–High Resolution Mass Spectrometry

open access: yesRapid Communications in Mass Spectrometry, Volume 40, Issue 21, 15 November 2026.
ABSTRACT Rationale The proteolytic behavior of chymosins during cheese ripening impacts cheese texture, flavor, and quality. Especially, the specific hydrolysis of αS1‐casein to αS1‐I‐casein is relevant for early cheese texture development, and this activity varies between chymosin variants.
Sebastiaan Dolman   +7 more
wiley   +1 more source

Automated Multienzyme Digestion Workflows for Confident Characterization of Challenging Posttranslational Modifications in Therapeutic Antibodies by LC–MS/MS

open access: yesRapid Communications in Mass Spectrometry, Volume 40, Issue 21, 15 November 2026.
ABSTRACT Rationale Non‐reduced trypsin digestion of therapeutic antibodies can generate large disulfide‐linked peptide complexes that exhibit poor chromatographic and mass spectrometric performance. This limits the confident characterization of posttranslational modifications (PTMs) in specific antibody regions, such as the heavy‐chain constant region ...
Nanna Sofie Eskesen   +10 more
wiley   +1 more source

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1368-1378, November 2026.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer   +9 more
wiley   +1 more source

Molecular Adaptations and Sex‐Biased Regulatory Pathways in Multi‐Year Diapause of the Cabbage Beetle Colaphellus bowringi: A Duration‐Resolved Transcriptomic Analysis

open access: yesEcology and Evolution, Volume 16, Issue 11, November 2026.
This study presents the first multi‐duration, sex‐stratified transcriptomic analysis of prolonged diapause in Colaphellus bowringi, revealing that extended dormancy is maintained by coordinated metabolic suppression and sustained activation of cytoprotective pathways (e.g., glutathione metabolism, autophagy).
Lili Huang   +5 more
wiley   +1 more source

Baicalin Alleviates Lactational Heat‐Stress‐Induced Hepatic Mitochondrial Dysfunction via Sirt3‐Dependent Deacetylation of NDUFS1

open access: yesFood Frontiers, Volume 7, Issue 6, November 2026.
This study reveals that lactational HS suppresses Sirt3 activity, leading to hyperacetylation of the complex I subunit NDUFS1, and excessive mitochondrial ROS production, whereas BAI, a nature food‐derived bioactive compound, alleviates lactational HS‐induced hepatic mitochondrial injury by activating the Sirt3–NDUFS1 axis to deacetylate mitochondrial ...
Jingzheng Li   +3 more
wiley   +1 more source

Beneficial Role of Natural Polyphenols Against Epilepsy: Greasing the Wheels of Pharmacotherapy Research for Epilepsy

open access: yesFood Frontiers, Volume 7, Issue 6, November 2026.
ABSTRACT Epilepsy is the most disabling neurological disease that affects all economic classes, age groups, regions, and races. Although many antiseizure drugs are approved for epilepsy treatment, they fail to work in about 30%–40% of patients. Thus, there is a great need to identify better pharmacological agents to treat epilepsy.
Janakiraman Pillai Udaiyappan   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy